Medicine and device safety updates | 19 November 2026
- 19-11-2026
- Posted by: Eldaniz Hasanov
- Category: Regulatory Updates
19 verified groups of official materials: 18 current groups and one retrospective monthly TGA register with 33 rows. Source publication/update dates span 10–19 November 2026; September approval dates and earlier manufacturer-letter dates are distinguished below.
Fucithalmic: retail recall of one batch
HSA · HSA recall; SIN00726P
HSA published a Class 2 retail recall of Fucithalmic Eye Drops 1%, batch L54121, because of suspected aseptic process simulation failure. The recall started on 18 November; the card was published on 19 November. Hospitals, clinics and pharmacies are instructed to stop supplying the affected batch and return remaining stocks to the company.
Piperacillin/tazobactam: possible rhabdomyolysis link
Health Canada · SSR1794249006435
Health Canada found a possible link with rhabdomyolysis and will work with manufacturers to add the risk to Canadian product monographs. Three of four reviewed international cases were considered possibly linked; one was unassessable, confounding factors were present, and no deaths were reported. The review was published on 18 November; the page modification date is 19 November.
Arrow guidewires and PICC kits: coating concern
Health Canada · RA-82973
Health Canada published a Type II recall of specified Arrow guidewires and PICC kits. Teleflex reported that the hydrophilic coating may swell unevenly in saline, clump and potentially detach. The card was published on 18 November; recall commencement was 7 November. The official notice lists the affected models and directs readers to the manufacturer for the numerous lots.
Blueprint: two surgical-planning software errors
Health Canada · RA-82972
Health Canada reported a Type II recall concerning Blueprint 4.2.2 and 4.3.1. In 4.3.1, PSI guides can use an incorrect axis for the specified monopost/BIO-RSA Angled graft configuration. Both versions may allow pyrocarbon heads with HRS Flex procedures although those heads are labelled for Tornier Flex only. Card: 18 November; recall: 6 November.
Raz shower commode chairs: seat breakage risk
Health Canada · RA-82971
Health Canada published a Type II recall: certain molded and VFI seats supplied with Raz shower commode chairs do not meet the manufacturer’s specifications and may break, causing injury. Users are told to stop using a chair with an affected seat; replacement seats are offered. The official model/serial list defines scope. Card: 18 November; recall: 4 November.
DxC analyzers: repeated unit-conversion error
Health Canada · RA-82970
Health Canada reported a Type II recall involving specified DxC analyzers with software 1.5.0 or earlier. If a non-default reporting unit is selected and multiple tests or replicates share a sample ID, a conversion factor may be applied more than once, producing an erroneous value. Card: 18 November; recall: 2 November.
RayStation: possible underestimation of deformed dose
ANSM · R2630098 / RSL-P-RS FSN180167
ANSM published RaySearch’s notice for specified RayStation 4.7–v2026 builds. When deformable registration extends outside the original dose grid, clinically relevant dose can be lost, leading to unintended underestimation. The manufacturer describes precautions for dose evaluation/planning and a planned correction. No known patient treatment errors were reported. ANSM publication: 18 November; manufacturer letter: 1 October.
Trokamed: CIDEX OPA contraindication added to instructions
ANSM · R2630568 / FSN2026-01
Trokamed updated reprocessing instructions to include the CIDEX OPA manufacturer’s contraindication for urological instruments used in patients with a history of bladder cancer. Residual OPA can be associated with severe allergic/anaphylactic reactions. Staff should use the revised instructions. The notice explicitly says this is not a product recall and no related incident is known. ANSM card: 18 November; letter: 15 October.
Carestation 850/850c: reduced anesthetic delivery
ANSM · R2632280 / GE34149
GE HealthCare warns of possible anesthetic underdelivery when two vaporisers are installed and the left one is selected. If alarms go unnoticed during use, movement or intraoperative awareness could occur. Daily checks, agent monitoring and the specific contingency instructions remain important until correction. No injuries were reported. The manufacturer’s notice covers Carestation 850 and 850c; ANSM published it on 18 November 2026.
Furosemide: measures to preserve treatment continuity
ANSM · Recommendation of 10 November 2026
ANSM strengthened measures for continuing shortages of 20 mg and 40 mg tablets. Its recommendation allows exceptional temporary substitution by appropriately dosed compounded capsules without a new prescription, subject to the pharmacist’s recording, prescriber notification and patient-information conditions. Separate 20 mg/40 mg patient sheets accompany the recommendation. Card/upload: 18 November; recommendation: 10 November; patient sheets: 5 November. These are French measures, not instructions for other jurisdictions.
Mammography systems: potential C-arm freefall
TGA · RC-2026-RN-00944-1
TGA lists a Class II hospital product correction for specified Hologic systems. Severe wear of the vertical lift nut may cause sudden C-arm freefall and injury. The notice permits continued use pending inspection, but instructs users to stop and contact support if abnormal vertical travel, movement or loud noise occurs. Five system-failure complaints since 2019 and no serious injuries are reported. Action commenced on 17 November 2026.
corpuls3: temporary display interruption during ECG printing
TGA · RC-2026-RN-00862-1
TGA’s Class II hospital correction addresses electrostatic interference during resting-ECG printing, which can interrupt Bluetooth/display operation for 5–25 seconds. The notice warns of possible delay to life-saving treatment. A backup device is advised where possible; the P509 circuit board will be replaced. There were 67 worldwide complaints, none in Australia, and no reported patient harm. Action commenced on 17 November 2026.
Remel Type A reagent: possible false-negative typing
TGA · RC-2026-RN-00945-1
TGA lists a Class III hospital recall of batch 6134913 because the reagent can fail the required agglutination criterion, potentially producing false-negative results. Customers should quarantine stock and follow the return/destruction and review instructions. The notice explicitly states that delayed correct serogroup identification should not affect patient management. Action commenced on 17 November 2026.
Fymskina: long-term safety information aligned with Stelara
EMA · EMA/VR/0000362273
The updated lifecycle document records extension to adult ulcerative colitis and long-term safety updates aligned with the reference product Stelara, with corresponding RMP changes. The procedure opinion was 9 October and Commission decision 12 November; the EPAR documents were posted/updated on 18 November. This is an update to authorised information, not a newly established safety signal.
Fintepla: interaction information updated
EMA · EMA/VR/0000340431
EMA’s lifecycle document records an update to SmPC section 4.5 and the leaflet concerning the effect of fenfluramine on CYP2B6, CYP3A4 and MATE1 substrates, based on interaction study UP0132. The procedure opinion is dated 8 October; the EPAR information and lifecycle record were updated on 18 November.
Sotyktu: long-term study deadline revised
EMA · EMA/VR/0000384118
EMA’s 18 November lifecycle update records extension of the due date for category 3 RMP study IM011075 from December 2026 to July 2027. The study assesses long-term safety and efficacy in moderate-to-severe plaque psoriasis. This is a pharmacovigilance-plan milestone change; it does not establish a new adverse reaction or change prescribing instructions.
EURD list: revision 166 published
EMA · EMA/630645/2012 Rev.166
EMA published revision 166 of the Union reference dates and PSUR submission-frequency list, dated 18 November 2026. Marketing authorisation holders should check the entries applicable to their products and the listed data-lock/submission dates. This release reports the verified new list version; it does not infer a new safety signal or claim that every row changed.
Santa Cruz Paleo powders: undeclared milk allergen
FDA · Company announcement: 9 November / FDA publication: 18 November
FDA published Rocky Mountain Nutrition’s recall announcement for Pineapple Caffeine lot 2606161 and Island Punch Caffeine lot 2512293, in 381 g jars. A milk-derived ingredient was not declared as an allergen, creating a serious or life-threatening reaction risk for susceptible consumers. The company asks consumers to stop use and dispose of affected product. The announcement is dated 9 November and was posted by FDA on 18 November; no associated illnesses or allergic reactions had been reported to the company as of 6 November.
Retrospective review: September Australian PI safety updates
TGA · Monthly PI safety updates, September 2026
TGA’s September 2026 register contains 33 substance/combination rows covering safety-related changes to Australian Product Information. The official page was last updated on 10 November 2026; the listed approval dates are 1–27 September. This retrospective review covers revised warnings, interactions and adverse reactions. Healthcare professionals should consult the official table and current Australian PI for the relevant brand.
Professional relevance
QPPV, LQPPV and LCPPV teams may use this review to assess local safety information, interactions and risk-minimisation measures. Role applicability and duties vary by jurisdiction; a national regulatory action should not automatically be applied elsewhere.